Ximedica Joins Theorem Clinical Research Strategic Alliance Group
News Sep 12, 2013
Theorem Clinical Research has announced the addition of Ximedica, a medical product development firm, to its roster of strategic alliances.
With deep expertise in human factors engineering, industrial design, mechanical, electrical and software engineering, advanced manufacturing services and regulatory requirements, Ximedica brings more than 25 years of experience developing medical devices, combination products and consumer health care products to the alliance.
Ximedica’s product development experience includes programs involving complex electro-mechanical systems, fluid management systems, graphical user interfaces, portable or wearable systems and systems with cutting-edge wireless technology and miniaturization solutions.
“Theorem works with Ximedica to create design solutions that meet the safety and use requirements of a wide range of populations, thereby minimizing risk during the regulatory review process,” said D. Lee Spurgin Jr., Ph.D., Theorem senior vice president and general manager of medical device and diagnostic development.
Spurgin continued, “We feel these types of business alliances allow us to offer a better end product to clients.”
“Recognizing that a growing number of our product development programs are requiring large-scale, multi-center global clinical studies, it made sense for Ximedica to partner with a reputable, global CRO such as Theorem. Our combined expertise provides a more compelling solution for our global clients,” said Ximedica CEO Randall S. Barko.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE